ORLANDO — At 12 months, AURN001, an allogenic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction, achieved all primary and secondary endpoints in the phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback